281 related articles for article (PubMed ID: 30012435)
21. Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection.
Toyoda H; Atsukawa M; Watanabe T; Nakamuta M; Uojima H; Nozaki A; Takaguchi K; Fujioka S; Iio E; Shima T; Akahane T; Fukunishi S; Asano T; Michitaka K; Tsuji K; Abe H; Mikami S; Okubo H; Okubo T; Shimada N; Ishikawa T; Moriya A; Tani J; Morishita A; Ogawa C; Tachi Y; Ikeda H; Yamashita N; Yasuda S; Chuma M; Tsutsui A; Hiraoka A; Ikegami T; Genda T; Tsubota A; Masaki T; Tanaka Y; Iwakiri K; Kumada T
J Gastroenterol Hepatol; 2020 May; 35(5):855-861. PubMed ID: 31609495
[TBL] [Abstract][Full Text] [Related]
22. Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials.
Suleiman AA; Lin CW; Liu W; Eckert D; Mensing S; Burroughs M; Kato K; Chayama K; Kumada H; Oberoi RK
J Clin Pharmacol; 2020 Mar; 60(3):331-339. PubMed ID: 31515816
[TBL] [Abstract][Full Text] [Related]
23. Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals.
Kosloski MP; Oberoi R; Wang S; Viani RM; Asatryan A; Hu B; Ding B; Qi X; Kim EJ; Mensa F; Kort J; Liu W
J Infect Dis; 2020 Jan; 221(2):223-231. PubMed ID: 31504702
[TBL] [Abstract][Full Text] [Related]
24. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.
Sezaki H; Suzuki F; Hosaka T; Fujiyama S; Kawamura Y; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Gastroenterol; 2019 Oct; 54(10):916-927. PubMed ID: 30903385
[TBL] [Abstract][Full Text] [Related]
25. The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study.
Nozaki A; Atsukawa M; Kondo C; Toyoda H; Chuma M; Nakamuta M; Uojima H; Takaguchi K; Ikeda H; Watanabe T; Ogawa S; Itokawa N; Arai T; Hiraoka A; Asano T; Fujioka S; Ikegami T; Shima T; Ogawa C; Akahane T; Shimada N; Fukunishi S; Abe H; Tsubota A; Genda T; Okubo H; Mikami S; Morishita A; Moriya A; Tani J; Tachi Y; Hotta N; Ishikawa T; Okanoue T; Tanaka Y; Kumada T; Iwakiri K; Maeda S;
Hepatol Int; 2020 Mar; 14(2):225-238. PubMed ID: 32128704
[TBL] [Abstract][Full Text] [Related]
26. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
Ng TI; Pilot-Matias T; Tripathi R; Schnell G; Krishnan P; Reisch T; Beyer J; Dekhtyar T; Irvin M; Lu L; Asatryan A; Campbell A; Yao B; Lovell S; Mensa F; Lawitz EJ; Kort J; Collins C
Viruses; 2018 Aug; 10(9):. PubMed ID: 30154359
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.
Toyoda H; Chayama K; Suzuki F; Sato K; Atarashi T; Watanabe T; Atsukawa M; Naganuma A; Notsumata K; Osaki Y; Nakamuta M; Takaguchi K; Saito S; Kato K; Pugatch D; Burroughs M; Redman R; Alves K; Pilot-Matias TJ; Oberoi RK; Fu B; Kumada H
Hepatology; 2018 Feb; 67(2):505-513. PubMed ID: 28865152
[TBL] [Abstract][Full Text] [Related]
28. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.
Forns X; Lee SS; Valdes J; Lens S; Ghalib R; Aguilar H; Felizarta F; Hassanein T; Hinrichsen H; Rincon D; Morillas R; Zeuzem S; Horsmans Y; Nelson DR; Yu Y; Krishnan P; Lin CW; Kort JJ; Mensa FJ
Lancet Infect Dis; 2017 Oct; 17(10):1062-1068. PubMed ID: 28818546
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection.
Flamm SL; Kort J; Marx SE; Strezewski J; Dylla DE; Bacon B; Curry MP; Tsai N; Wick N
Adv Ther; 2020 May; 37(5):2267-2274. PubMed ID: 32279176
[TBL] [Abstract][Full Text] [Related]
30. Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.
Poordad F; Pol S; Asatryan A; Buti M; Shaw D; Hézode C; Felizarta F; Reindollar RW; Gordon SC; Pianko S; Fried MW; Bernstein DE; Gallant J; Lin CW; Lei Y; Ng TI; Krishnan P; Kopecky-Bromberg S; Kort J; Mensa FJ
Hepatology; 2018 Apr; 67(4):1253-1260. PubMed ID: 29152781
[TBL] [Abstract][Full Text] [Related]
31. Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens.
Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
J Med Virol; 2019 Jan; 91(1):102-106. PubMed ID: 30091810
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects.
Lin CW; Dutta S; Ding B; Wang T; Zadeikis N; Asatryan A; Kort J; Campbell A; Podsadecki T; Liu W
J Clin Pharmacol; 2017 Dec; 57(12):1616-1624. PubMed ID: 28800195
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study.
Rockstroh JK; Lacombe K; Viani RM; Orkin C; Wyles D; Luetkemeyer AF; Soto-Malave R; Flisiak R; Bhagani S; Sherman KE; Shimonova T; Ruane P; Sasadeusz J; Slim J; Zhang Z; Samanta S; Ng TI; Gulati A; Kosloski MP; Shulman NS; Trinh R; Sulkowski M
Clin Infect Dis; 2018 Sep; 67(7):1010-1017. PubMed ID: 29566246
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.
Heo J; Kim YJ; Lee JW; Kim JH; Lim YS; Han KH; Jeong SH; Cho M; Yoon KT; Bae SH; Crown ED; Fredrick LM; Alami NN; Asatryan A; Kim DH; Paik SW; Lee YJ
Gut Liver; 2021 Nov; 15(6):895-903. PubMed ID: 34053916
[TBL] [Abstract][Full Text] [Related]
35. Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C.
Hubbard H; Lawitz E
Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):9-17. PubMed ID: 29187007
[TBL] [Abstract][Full Text] [Related]
36. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.
Puoti M; Foster GR; Wang S; Mutimer D; Gane E; Moreno C; Chang TT; Lee SS; Marinho R; Dufour JF; Pol S; Hezode C; Gordon SC; Strasser SI; Thuluvath PJ; Zhang Z; Lovell S; Pilot-Matias T; Mensa FJ
J Hepatol; 2018 Aug; 69(2):293-300. PubMed ID: 29551706
[TBL] [Abstract][Full Text] [Related]
37. Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects.
Kosloski MP; Zhao W; Marbury TC; Preston RA; Collins MG; Pugatch D; Mensa F; Kort J; Liu W
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263061
[TBL] [Abstract][Full Text] [Related]
38. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.
Gane E; Poordad F; Wang S; Asatryan A; Kwo PY; Lalezari J; Wyles DL; Hassanein T; Aguilar H; Maliakkal B; Liu R; Lin CW; Ng TI; Kort J; Mensa FJ
Gastroenterology; 2016 Oct; 151(4):651-659.e1. PubMed ID: 27456384
[TBL] [Abstract][Full Text] [Related]
39. Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials.
Brown A; Welzel TM; Conway B; Negro F; Bräu N; Grebely J; Puoti M; Aghemo A; Kleine H; Pugatch D; Mensa FJ; Chen YJ; Lei Y; Lawitz E; Asselah T
Liver Int; 2020 Apr; 40(4):778-786. PubMed ID: 31568620
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers.
Lin CW; Dutta S; Zhao W; Asatryan A; Campbell A; Liu W
Eur J Drug Metab Pharmacokinet; 2018 Feb; 43(1):81-90. PubMed ID: 28688001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
